Evidence map›Paper›PMID 42592154›Full record

ArticleActa pharmaceutica Sinica. B2026

Metabolic-epigenetic reprogramming

Xinyuan Zhao, Xin Liao, Yunfan Lin, Xu Chen, Pei Lin, Ye Lu, Jiarong Zheng, Meiyan Zou, Bing Guo, Li Cui

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Acta pharmaceutica Sinica. B, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Xinyuan ZhaoStomatological Hospital, School of Stomatology, Southern Medical University, Guangzhou 510280, China.
Xin LiaoDepartment of Dentistry, The First Affiliated Hospital, Sun Yat-sen University, Guangzhou 510080, China.
Yunfan LinStomatological Hospital, School of Stomatology, Southern Medical University, Guangzhou 510280, China.
Xu ChenStomatological Hospital, School of Stomatology, Southern Medical University, Guangzhou 510280, China.
Pei LinStomatological Hospital, School of Stomatology, Southern Medical University, Guangzhou 510280, China.
Ye LuStomatological Hospital, School of Stomatology, Southern Medical University, Guangzhou 510280, China.
Jiarong ZhengDepartment of Dentistry, The First Affiliated Hospital, Sun Yat-sen University, Guangzhou 510080, China.
Meiyan ZouStomatological Hospital, School of Stomatology, Southern Medical University, Guangzhou 510280, China.
Bing GuoDepartment of Dentistry, The First Affiliated Hospital, Sun Yat-sen University, Guangzhou 510080, China.
Li CuiStomatological Hospital, School of Stomatology, Southern Medical University, Guangzhou 510280, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Cisplatin remains a cornerstone of treatment for head and neck squamous cell carcinoma (HNSCC), yet its therapeutic efficacy is often undermined by acquired resistance. Here, we identify the PLOD1-PFKP-glycolysis axis as a central driver of cisplatin resistance. PLOD1 is significantly upregulated in cisplatin-resistant tumors and correlates with poor prognosis. Mechanistically, PLOD1 stabilizes the glycolytic enzyme PFKP by promoting its AKT-mediated phosphorylation at serine 386

Indexed as

Cisplatin resistanceEpigenetic regulationGlycolysisHead and neck squamous cell carcinomaMetabolic reprogrammingPFKPPLOD1TGFBR2

Identifiers

PMID42592154
PMCPMC13464578

What Socratic holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.